MX2019014026A - Metodos para la deteccion de melanoma. - Google Patents

Metodos para la deteccion de melanoma.

Info

Publication number
MX2019014026A
MX2019014026A MX2019014026A MX2019014026A MX2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A
Authority
MX
Mexico
Prior art keywords
methods
melanoma
melanoma detection
subject
detection
Prior art date
Application number
MX2019014026A
Other languages
English (en)
Spanish (es)
Inventor
Mark Kidd
Irvin Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2019014026A publication Critical patent/MX2019014026A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
MX2019014026A 2017-05-25 2018-05-21 Metodos para la deteccion de melanoma. MX2019014026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (1)

Publication Number Publication Date
MX2019014026A true MX2019014026A (es) 2020-08-03

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014026A MX2019014026A (es) 2017-05-25 2018-05-21 Metodos para la deteccion de melanoma.

Country Status (14)

Country Link
US (2) US20180340934A1 (enExample)
EP (1) EP3631017B1 (enExample)
JP (1) JP7227964B2 (enExample)
KR (1) KR102763004B1 (enExample)
CN (1) CN111315897B (enExample)
AU (1) AU2018273844B2 (enExample)
BR (1) BR112019024481A2 (enExample)
CA (1) CA3064732A1 (enExample)
DK (1) DK3631017T3 (enExample)
ES (1) ES2920288T3 (enExample)
IL (1) IL270787B2 (enExample)
MX (1) MX2019014026A (enExample)
PL (1) PL3631017T3 (enExample)
WO (1) WO2018217627A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024481A2 (pt) 2017-05-25 2020-07-14 Liquid Biopsy Research LLC métodos para detecção de melanoma
US20210108259A1 (en) 2019-10-10 2021-04-15 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614946A1 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Biomarkers for melanoma
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
EP2080140B1 (en) * 2006-11-03 2013-04-24 Baylor Research Institute Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
US20110091384A1 (en) * 2009-10-13 2011-04-21 The Johns Hopkins University Biomarker for identification of melanoma tumor cells
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN104470920A (zh) * 2012-07-03 2015-03-25 通益制药有限公司 固态形式的维罗菲尼胆碱盐
AU2015317893B2 (en) * 2014-09-15 2021-05-20 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
BR112019024481A2 (pt) 2017-05-25 2020-07-14 Liquid Biopsy Research LLC métodos para detecção de melanoma

Also Published As

Publication number Publication date
DK3631017T3 (da) 2022-06-20
JP7227964B2 (ja) 2023-02-22
EP3631017A1 (en) 2020-04-08
PL3631017T3 (pl) 2022-09-26
WO2018217627A1 (en) 2018-11-29
IL270787B2 (en) 2023-08-01
AU2018273844A1 (en) 2019-12-19
JP2020524524A (ja) 2020-08-20
US20180340934A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
ES2920288T3 (es) 2022-08-02
IL270787B1 (en) 2023-04-01
KR102763004B1 (ko) 2025-02-04
EP3631017B1 (en) 2022-03-23
CN111315897B (zh) 2024-10-22
KR20200030034A (ko) 2020-03-19
US12399179B2 (en) 2025-08-26
IL270787A (en) 2020-01-30
CN111315897A (zh) 2020-06-19
AU2018273844B2 (en) 2024-11-14
US20230022236A1 (en) 2023-01-26
CA3064732A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
EP4015531A3 (en) Mutant pore
PH12017502391A1 (en) Compositions and methods for inhibiting arginase activity
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
TR201909887T4 (tr) ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri.
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
WO2016028610A3 (en) Implantable medical device with self-correlation means and with peak selector means for estimating cardiac rate
MX351044B (es) Sistemas y métodos para determinar las propiedades de los fluidos.
MX2023005399A (es) Cumplimiento con prenda de compresion.
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
MX382410B (es) Determinación de niveles de glicosaminoglicanos mediante espectrometría de masas.
PL3523639T3 (pl) Odczynniki wykrywające i układy elektrod do elementów diagnostycznych testów wieloanalitowych oraz sposoby ich zastosowania
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201691314A1 (ru) Терапевтические способы и композиции
MX2020007771A (es) Metodos para la supervision de la deteccion y el tratamiento de cancer de colon.
MX364119B (es) Aparatos y métodos de análisis de datos.
AU363883S (en) Tracking device
CA2997405C (en) DETERMINATION OF GASES DISSOLVED IN BLOOD IN EXTRACORPOREAL CIRCULATION
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
PH12017500765A1 (en) Malaria detection
EP3394765A4 (en) DETECTION OF HIDDEN LINK FEMALE MATCHES WITH FAKE METADATA
MX2020000785A (es) Metodos para la deteccion de discrasia de celulas plasmaticas.
GB2557076A (en) Tubular wear volume determination using adjustable wear factors
MA40636A (fr) Procédés pour détecter le cancer de la prostate
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy